In the emulation of SURPASS-CVOT comparing tirzepatide to dulaglutide in patients at high cardiovascular risk (Table 2 and Supplementary Table 19), the estimated HR was 0.83 (95% CI 0.69 to 1.01) compared to the trial estimates of HR 0.92 (95% CI 0.83 to 1.01)
TB-500 has been particularly extensively studied in cardiac repair models with foundational research demonstrating that thymosin beta-4 and TB-500 promote cardiomyocyte survival following ischaemia-reperfusion injury, stimulate cardiac progenitor cell migration into infarcted tissue, reduce infarct size, and improve cardiac function in myocardial infarction models
Metformin and semaglutide are frequently used together and generally considered safe in combination, as they work through different mechanisms
Body Weight Management in Adults Under Chronic Stress Through Treatment With Ashwagandha Root Extract: A Double-Blind, Randomized, Placebo-Controlled Trial: Choudhary, D., Bhattacharyya, S., & Joshi, K